Drug intelligence / Profile preview

BMS-852927

Development stage: Discontinued
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-852927 is an oral, small molecule modulator of the liver X receptor (LXR), with high selectivity for the LXRβ isoform and partial activity at LXRα. It was developed primarily for the treatment of atherosclerosis and hypercholesterolemia. The drug acts as an agonist at LXRβ, promoting cholesterol efflux and regulating lipid metabolism by inducing target genes such as ABCG1. Despite its potent activity in preclinical models, clinical development was discontinued due to increases in LDL-cholesterol and triglycerides observed in humans and primate models, along with potential safety concerns[1][2][5][7].

Other names: 1256918-39-4

Targets

LXRB (Liver X receptor beta)NR1H3 (Liver X receptor beta)

Beyond the preview

Go deeper on BMS-852927.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-852927.

Explore the full profile